Activity at Kodak Pharmaceuticals regarding US government loan to be reviewed
After "allegations of wrongdoing" were connected to Eastman Kodak Company following a $765 million loan from the US government, a review has been announced.
List view / Grid view
After "allegations of wrongdoing" were connected to Eastman Kodak Company following a $765 million loan from the US government, a review has been announced.
New research has shown that complex collaborations and partnerships are increasing, while licensing agreements are decreasing in the rare disease space.
A new report has outlined that AstraZeneca has been granted protection from product liability claims regarding its COVID-19 vaccine candidate.
Pfizer is to manufacture and supply the investigational COVID-19 treatment remdesivir for Gilead Sciences at one of its facilities.
A new vaccine platform using self-assembling peptide nanofibres tagged with antigens has been tested successfully in mice, eliciting a strong immune response.
J&J will supply the US with 100 million doses of the company’s COVID-19 vaccine candidate following an agreement with the country's government.
Novartis' Xolair (omalizumab) has been approved by the European Commission as an add-on therapy with intranasal corticosteroids to treat severe chronic rhinosinusitis with nasal polyps.
Regulatory bodies in India are tracking the cost of remdesivir and favipiravir amid the COVID-19 pandemic but should consider price caps, a report has suggested.
President Donald Trump has signed the 'Buy American' executive order, which is meant to reduce drug prices and protect the US from supply chain disruptions.
NICE has issued draft guidance that does not recommend chlormethine gel for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.
Tinostamustine has been granted Orphan Drug Designation by the European Commission to the treatment of T-cell prolymphocytic leukaemia (T-PLL).
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.
Researchers have shown that symptoms in patients experiencing severe COVID-19 improved when given either sarilumab or tocilizumab, interleukin-6 inhibitors.
The UK government has written an open letter to medicine suppliers, outlining how supply can be maintained after the end of the Brexit transition period.